Komori
Other Disclosures4575CanBas Co.,Ltd.Pharmaceuticals

Corporate Presentation: November 2026 Edition

CanBas Co.,Ltd. published a corporate presentation covering its company profile as of November 2026, development pipeline, preparations for the European Phase 3 trial of CBP501, financing, and earnings outlook. This is an update of information for investors, not an announcement of a new agreement or product offering.

Worth reading
65In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Announced details

CBP501CBT005CBS9106CBP-A08IDO/TDO dual inhibitor
Applicable field (uses covered by this announcement)

Third-line treatment for pancreatic cancer, other cancer immunotherapy areas, and research into novel COVID-19 treatments

Launch dateApproval to initiate the European Phase 3 clinical trial of CBP501 has been obtained, and preparations for initiation are under way in 8 European countries. The start date is Not disclosed.
Contract DateFinancing agreement date: 2 November 2026. Out-licensing of CBS9106: December 2014; expansion of the covered territory: August 2018; agreement termination and return of rights: June 2025.
What the company reported numerically
Quantitative Effects

The primary endpoint of the 3-month progression-free survival rate was achieved in the CBP501 Phase 2 trial.

Relationship between the counterparty and the company
CanBas Co.,Ltd.4575
Relationship with the Company

SBI SECURITIES Co., Ltd. is the allottee of the stock acquisition rights and the lender under the financing. CanBas and University of Shizuoka are conducting joint research on a dual IDO/TDO inhibitor. CanBas and INTAGE Healthcare are conducting joint research on drug discovery using AI. The license agreement for CBS9106 with Stemline has been terminated, and all rights have been returned.

Counterparty株式会社SBI証券Shizuoka Prefectural UniversityINTAGE HealthcareStemline

Detailed company profiles for SBI SECURITIES Co., Ltd., University of Shizuoka, INTAGE Healthcare, and Stemline are largely not provided. University of Shizuoka is a joint research partner.

Registration number and expiry date

Patents for the IDO/TDO dual inhibitor have been granted in Japan and the United States. Patent numbers and expiry dates are Not disclosed. CBP501 has received orphan drug designation in Europe and the United States. Registration numbers and expiry dates are Not disclosed.

Location (as indicated in this announcement)

2-2-1 Otemachi, Numazu, Shizuoka, Japan

19 employees, comprising 14 in research and development and 5 in administration. The CBP501 Phase 3 trial is planned to involve approximately 50 sites in 8 countries, with approximately 180 participants in total across 2 groups.
Contract Value

Expected proceeds of ¥4,175 million, after deducting ¥22 million in issuance costs. The financing facility limit is ¥500 million. Upfront payments under the CBS9106 agreement were ¥10 million and ¥5 million, and cumulative technical advisory fees were ¥702 million.

Impact on Business Performance

For the fiscal year ended June 2026, no business revenue was recorded. Operating loss was ¥1,358 million, ordinary loss was ¥1,307 million, and net loss was ¥1,308 million. The disclosure states that additional basic research on CBS9106 will have no short-term impact on financial results.

The company does not address Offering price.

Source (materials cited by the company)

Clinical Trials Information System (CTIS), ECIS (European Cancer Information System), Globocan 2022, IARC GLOBOCAN2018, various medical papers, ESMO2020, and the American Society of Health-System Pharmacists (ASHP), among others

Announced details
ItemDetails
Names of Products / Services CoveredCBP501, CBT005, CBS9106, CBP-A08, IDO/TDO dual inhibitor
Counterparty株式会社SBI証券, Shizuoka Prefectural University, INTAGE Healthcare, Stemline
Counterparty overviewDetailed company profiles for SBI SECURITIES Co., Ltd., University of Shizuoka, INTAGE Healthcare, and Stemline are largely not provided. University of Shizuoka is a joint research partner.
Relationship with the CompanySBI SECURITIES Co., Ltd. is the allottee of the stock acquisition rights and the lender under the financing. CanBas and University of Shizuoka are conducting joint research on a dual IDO/TDO inhibitor. CanBas and INTAGE Healthcare are conducting joint research on drug discovery using AI. The license agreement for CBS9106 with Stemline has been terminated, and all rights have been returned.
Contract ValueExpected proceeds of ¥4,175 million, after deducting ¥22 million in issuance costs. The financing facility limit is ¥500 million. Upfront payments under the CBS9106 agreement were ¥10 million and ¥5 million, and cumulative technical advisory fees were ¥702 million.
Contract DateFinancing agreement date: 2 November 2026. Out-licensing of CBS9106: December 2014; expansion of the covered territory: August 2018; agreement termination and return of rights: June 2025.
Launch dateApproval to initiate the European Phase 3 clinical trial of CBP501 has been obtained, and preparations for initiation are under way in 8 European countries. The start date is Not disclosed.
Applicable areaThird-line treatment for pancreatic cancer, other cancer immunotherapy areas, and research into novel COVID-19 treatments
Registration number and expiry datePatents for the IDO/TDO dual inhibitor have been granted in Japan and the United States. Patent numbers and expiry dates are Not disclosed. CBP501 has received orphan drug designation in Europe and the United States. Registration numbers and expiry dates are Not disclosed.
Location2-2-1 Otemachi, Numazu, Shizuoka, Japan
Location scale19 employees, comprising 14 in research and development and 5 in administration. The CBP501 Phase 3 trial is planned to involve approximately 50 sites in 8 countries, with approximately 180 participants in total across 2 groups.
Quantitative EffectsThe primary endpoint of the 3-month progression-free survival rate was achieved in the CBP501 Phase 2 trial.
Impact on Business PerformanceFor the fiscal year ended June 2026, no business revenue was recorded. Operating loss was ¥1,358 million, ordinary loss was ¥1,307 million, and net loss was ¥1,308 million. The disclosure states that additional basic research on CBS9106 will have no short-term impact on financial results.
SourceClinical Trials Information System (CTIS), ECIS (European Cancer Information System), Globocan 2022, IARC GLOBOCAN2018, various medical papers, ESMO2020, and the American Society of Health-System Pharmacists (ASHP), among others
Items this document does not state (4)
Offering priceAward/certification nameAwarding / certifying bodyUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To explain the company profile, research and development progress, financing, and financial position to investors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Presentation: November 2026 Edition | CanBas Co.,Ltd. (4575) timely disclosure | Komori